Frankfurt - Delayed Quote EUR

Hims & Hers Health, Inc. (82W.F)

23.61

+0.43

+(1.86%)

At close: April 17 at 5:21:13 PM GMT+2

Eli Lilly stock soars on positive weight-loss pill results

Eli Lilly (LLY) stock surges after releasing promising test results from the company's GLP-1 pill, which would serve as an alternative to injectable weight-loss drugs. Novo Nordisk (NVO) and Hims & Hers Health (HIMS) stocks are falling on the news. Yahoo Finance Senior Healthcare Reporter Anjalee Khemlani joins Morning Brief to break down the details. To watch more expert insights and analysis on the latest market action, check out more Morning Brief here.

Yahoo Finance Video 2 days ago

HIMS

LLY

NONOF
April 2025's Top Growth Stocks With Strong Insider Confidence

The United States market has shown a robust performance recently, climbing 8.4% in the last week and increasing by 5.9% over the past year, with earnings anticipated to grow by 13% annually. In this favorable environment, growth companies with high insider ownership can be particularly attractive as they often signal strong internal confidence and alignment of interests between management and shareholders.

Simply Wall St. 3 days ago

JEF

BILI

BLBLF
Hims & Hers to Announce First Quarter 2025 Financial Results on May 5, 2025

SAN FRANCISCO, April 14, 2025--Hims & Hers Health, Inc. ("Hims & Hers", NYSE: HIMS), the leading health and wellness platform, today announced that it will report first quarter 2025 financial results after the market closes on Monday, May 5, 2025. The company will host a live conference call to discuss the results at 5:00 p.m. ET the same day.

Business Wire 5 days ago

HIMS
Hims & Hers Health (NYSE:HIMS) Rises 5% Over Last Quarter Following Strong 2024 Earnings

Hims & Hers Health (NYSE:HIMS) recently experienced a 5% price increase over the past quarter, marked by significant corporate events. The company was added to the S&P 400 index and simultaneously dropped from the S&P 600, highlighting a shift in its market positioning. Alongside this, its focus on strategic acquisitions, as indicated by the pursuit of lab diagnostic facilities, aligns with its growth strategy. Despite the market facing a 6% decline due to global trade tensions, Hims & Hers...

Simply Wall St. 15 days ago

HIMS
Analysts Stay Cautious on HIMS Stock amid Core Business Uncertainty

Hims & Hers Health Inc. (HIMS) is facing increased skepticism from investors and analysts over the sustainability concerns of its core business growth. While the telehealth company has shown strong revenue expansion, questions remain about long-term profitability and customer retention. As a result, many analysts are adopting a cautious stance on HIMS stock, waiting for clearer signs of stability before making bullish calls. Let’s look at key 2024 data on HIMS to understand why investors and ana

TipRanks 16 days ago

HIMS
Hims Claws Back After Its Lilly-Rivaling Obesity Plan Faces An Unexpected Hitch

Hims stock clawed higher Wednesday though analysts laid out low expectations for Him & Hers' branded tirzepatide.

Investor's Business Daily 17 days ago

LLY

NONOF

NVO
Who Should Pay for Ozempic Is the Next Big Workplace Fight

Questions about insurance coverage for weight-loss drugs are getting more intense as cheaper alternatives go off the market.

The Wall Street Journal 18 days ago

HIMS
Hims & Hers Expands Weight Loss Offering, Adds Lilly’s Zepbound to Platform

Hims & Hers Health said it is expanding its weight-loss offerings with the addition of Eli Lilly & Co. Zepbound and generic liraglutide. The telehealth-consultation platform on Tuesday said it aimed to bring its customers more treatment options to best suit their needs. “We’ve now expanded that choice even further by adding access to generic liraglutide and branded tirzepatide through our platform,” the company said.

The Wall Street Journal 18 days ago

LLY

HIMS
Hims & Hers adds Eli Lilly GLP-1 drugs, Johnson & Johnson setback

Yahoo Finance Senior Reporter Anjalee Khemlani joins Market Domination to discuss some of the top stories of the trading day, including Johnson & Johnson's (JNJ) setback in its litigation. Additionally, Hims & Hers (HIMS) expanded its offerings, adding Eli Lilly's (LLY) GLP-1 drugs to its telehealth platform, following its earlier partnership with Novo Nordisk. To watch more expert insights and analysis on the latest market action, check out more Market Domination here.

Yahoo Finance Video 18 days ago

JNJ

LLY

HIMS
Hims Stock Jumps After Adding Eli Lilly's Obesity Drug To Its Platform

Hims stock surged Tuesday after the compounding pharmacy said it would sell Eli Lilly's branded weight-loss drug on its telehealth platform.

Investor's Business Daily 18 days ago

LFMD

LFMDP

TDOC
Hims & Hers Health, Inc.'s (NYSE:HIMS) Stock Has Been Sliding But Fundamentals Look Strong: Is The Market Wrong?

It is hard to get excited after looking at Hims & Hers Health's (NYSE:HIMS) recent performance, when its stock has...

Simply Wall St. 18 days ago

HIMS
Sale of Ozempic Knockoffs Is Supposed to End Soon. Telehealth Companies Aren’t Happy.

Pharmaceutical giants are squaring off against telehealth companies and pharmacies selling custom-made versions of the hot medicines.

The Wall Street Journal last month

HIMS

LLY
They Wanted a Quick Fix for Hair Loss. Instead, These Young Men Got Sick.

Hims and other telehealth companies make finasteride easy to get and don’t have to disclose side effects in ads.

The Wall Street Journal last month

HIMS
Defiance Launches RKLX and HIMZ: 2X Leveraged ETFs for Rocket Lab and Hims & Hers

Defiance Launches RKLX and HIMZ: 2X Leveraged ETFs for Rocket Lab and Hims & Hers ●RKLX, the Defiance Daily Target 2X Long RKLB ETF, seeks daily investment results that correspond to twice (200%) the daily percentage change of Rocket Lab, a company at the forefront of satellite launches, space exploration, and advanced aerospace systems.●HIMZ, the Defiance Daily Target 2X Long HIMS ETF, seeks daily investment results that correspond to twice (200%) the daily return of Hims & Hers, a company pion

GlobeNewswire last month

HIMS

RKLB
Define Ventures Appoints Carolyn Magill as Venture Partner

Define Ventures, one of the largest venture capital firms focused on early-stage health tech companies, today announced that Carolyn Magill, former CEO of Aetion, has joined the firm as venture partner. Magill, leveraging her 25 years of invaluable experience scaling companies and fostering innovation within payer, provider, and pharmaceutical organizations, will partner with Define founders to scale their companies and become category-defining companies.

PR Newswire last month

HIMS

EVH
Walgreens stock rises amid $10 billion deal with Sycamore Partners to take the drugstore chain private

Walgreens finalized a take-private deal with Sycamore Partners for $10 billion.

Yahoo Finance last month

UNH

CVS

KR
Hims Stock Claws Back After Novo Nordisk Undercuts It With A Cheaper Wegovy

Novo Nordisk slashed the price of Wegovy by more than half on Wednesday amid a bitter rivalry with Hims & Hers Health.

Investor's Business Daily last month

HIMS

LLY

NONOF
Healthcare Stock Could Be Good 'Buy the Dip' Play

HIMS trading within one standard deviation of its 50-day moving average

Schaeffer's Investment Research last month

HIMS
3 Growth Stocks Insiders Are Betting On

As the U.S. stock market grapples with economic concerns and newly imposed tariffs, investor sentiment has been cautious, leading to a broad-based decline across major indices. In such uncertain times, growth companies with high insider ownership can be appealing as they often signal confidence from those closest to the business.

Simply Wall St. last month

HIMS

GENI

ONON
Hims & Hers Health (NYSE:HIMS) Jumps 40% After Projecting US$2.3 Billion Revenue for 2025

Hims & Hers Health (NYSE:HIMS) experienced a 40% increase in share price last quarter, possibly fueled by strong financial performance and future growth projections. The company announced earnings on February 24, showcasing substantial growth with sales at $1,477 million for 2024, up from $872 million in 2023, and a turnaround in net income to $126 million from a loss the previous year. Their robust corporate guidance, projecting revenues of $2.3 billion to $2.4 billion for 2025, likely...

Simply Wall St. last month

HIMS

Performance Overview

Return	82W.F	S&P 500 (^GSPC)
YTD	-7.41%	-10.18%
1-Year	+100.59%	+5.19%
3-Year	+408.84%	+20.26%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Hims & Hers Health, Inc. (82W.F)

Eli Lilly stock soars on positive weight-loss pill results

April 2025's Top Growth Stocks With Strong Insider Confidence

Hims & Hers to Announce First Quarter 2025 Financial Results on May 5, 2025

Hims & Hers Health (NYSE:HIMS) Rises 5% Over Last Quarter Following Strong 2024 Earnings

Analysts Stay Cautious on HIMS Stock amid Core Business Uncertainty

Hims Claws Back After Its Lilly-Rivaling Obesity Plan Faces An Unexpected Hitch

Who Should Pay for Ozempic Is the Next Big Workplace Fight

Hims & Hers Expands Weight Loss Offering, Adds Lilly’s Zepbound to Platform

Hims & Hers adds Eli Lilly GLP-1 drugs, Johnson & Johnson setback

Hims Stock Jumps After Adding Eli Lilly's Obesity Drug To Its Platform

Hims & Hers Health, Inc.'s (NYSE:HIMS) Stock Has Been Sliding But Fundamentals Look Strong: Is The Market Wrong?

Sale of Ozempic Knockoffs Is Supposed to End Soon. Telehealth Companies Aren’t Happy.

They Wanted a Quick Fix for Hair Loss. Instead, These Young Men Got Sick.

Defiance Launches RKLX and HIMZ: 2X Leveraged ETFs for Rocket Lab and Hims & Hers

Define Ventures Appoints Carolyn Magill as Venture Partner

Walgreens stock rises amid $10 billion deal with Sycamore Partners to take the drugstore chain private

Hims Stock Claws Back After Novo Nordisk Undercuts It With A Cheaper Wegovy

Healthcare Stock Could Be Good 'Buy the Dip' Play

3 Growth Stocks Insiders Are Betting On

Hims & Hers Health (NYSE:HIMS) Jumps 40% After Projecting US$2.3 Billion Revenue for 2025

Performance Overview